天天中文日韩熟妇天堂,国产色精品视频91色,亚洲伊人久久在线,亚洲熟女五十路,亚洲人妻丝袜在线,亚洲综合日韩在线,亚洲欧美另类熟女精品,大量国产欧美日韩久久,日韩欧美亚洲

CN

CN EN

Latest News

Latest News Media Downloads Video Center

Kexing Biopharm's clinical trial application approved for small-molecule oral drug SHEN26 Capsule against COVID-19
2022-07-17

2022-07-17

On the evening of July 17, 2022, Kexing Biopharm Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that it had received the Notice of Approval for Drug Clinical Trial issued by the National Medical Products Administration, indicating that the clinical trial of small-molecule oral drug SHEN26 Capsule against COVID-19 jointly developed by Shenzhen Kexing and Shenzhen Antiv was approved.
Kexing Biopharm's clinical trial application accepted for Human Interferon α2b Effervescent Capsule
2022-06-27

2022-06-27

On the evening of June 20, 2022, Kexing Biopharm Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that it had received the Notice of Acceptance, an administrative license document issued by the National Medical Products Administration, indicating that its clinical trial application for "Human Interferon α2b Vaginal Effervescent Capsule" was accepted.
Ma Zhiyong, Secretary of CPC Zhangqiu District Committee of Jinan City, and his delegation visit Kexing Biopharm for research
2022-05-07

2022-05-07

On May 6, 2022, Ma Zhiyong, Secretary of the CPC Zhangqiu District Committee of Jinan City, Shandong Province, and his delegation visited Kexing Biopharm to research the Company's projects and enterprise operation. Cui Ning, Vice President of Kexing Biopharm and General Manager of Shandong Business Unit, was in charge of the reception.
Kexing Biopharm Signs Exclusive Promotion Service Agreement for Infliximab (Reminton?)
2022-03-31

2022-03-31

On March 31, 2022, Kexing Biopharmaceutical Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that the Exclusive Promotion Service Agreement for Infliximab (Reminton?) in Chinese Mainland was signed with Taizhou Mabtech, granting Kexing Biopharm the exclusive promotion right of infliximab (Reminton?) in Chinese mainland.
Kexing Biopharm Establishes Holding Company for Developing Veterinary Vaccines
2022-03-15

2022-03-15

Scientific Vaccine Innovations for Harmonious Coexistence Between Humans and Animals

1 2 3 4 5

Support Hotline

0755-26546500
Online Consultation
QR Code

Scan Code Consultation

高碑店市| 丰原市| 剑阁县| 兴城市| 美姑县| 司法| 七台河市| 获嘉县| 晴隆县| 涡阳县| 鄂托克旗| 庆阳市| 宕昌县| 辉县市| 武陟县| 金堂县| 黎平县| 靖西县| 平顶山市| 吴桥县| 施甸县| 泸定县| 龙口市| 黄平县| 黔东| 金门县| 合水县| 横峰县| 万山特区| 明水县| 新蔡县| 察隅县| 芒康县| 北票市| 贵德县| 新丰县| 元阳县| 德令哈市| 龙南县| 舒城县| 玛曲县|